Receiving Modified Chemotherapy Followed With Radical Resection After Neoadjuvant Chemotherapy
NCT ID: NCT03322969
Last Updated: 2021-02-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
60 participants
INTERVENTIONAL
2017-08-23
2023-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficiency of XELOX Neoadjuvant Chemotherapy in Gastric Cancer
NCT01665274
XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)
NCT03399110
FOLFOX6 as Neoadjuvant Chemotherapy in Local Advanced Gastric Cancer
NCT02226380
Neoadjuvant Chemotherapy Plus Chemoradiation in Patients With Potentially Resectable Gastric Carcinoma
NCT02024217
T- XELOX in HER2-positive Stage III Gastric Cancer After D2 Gastrectomy
NCT02250209
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
receiving modified chemotherapy
Paclitaxel/DDP
Paclitaxel/DDP
receiving the modified chemotherapy
receiving the original chemotherapy
XELOX/SOX
XELOX/SOX
receiving the original chemotherapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Paclitaxel/DDP
receiving the modified chemotherapy
XELOX/SOX
receiving the original chemotherapy
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ECOG performance status score ≤2 without serious heart, lung, liver, kidney, or hematological dysfunctions;
* age ≥18 years old;
* no previous chemotherapy, radiotherapy, or surgical treatment for gastric cancer;
* gastrectomy was performed after preoperative chemotherapy if imaging studies did not confirm disease progression (according to the Response Evaluation Criteria in Solid Tumors (RECIST)) ;
* signed the informed consent form.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking Union Medical College Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lin Zhao, Doctor
Role: STUDY_DIRECTOR
Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NAC-GC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.